Evidence map›Paper›PMID 29185010›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2018

Preliminary results on response assessment using

Anna Katharina Seitz, Isabel Rauscher, Bernhard Haller, Markus Krönke, Sophia Luther, Matthias M Heck, Thomas Horn, Jürgen E Gschwend, Markus Schwaiger, Matthias Eiber and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 3 pooled it
12.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 3 syntheses or guidelines pooled it, 139 citations in OpenAlex.

  1. Guideline
  2. Efficacy and Safety ofFrontiers in oncology · 2022
    Pooled it
  3. Evolving role ofProstate cancer and prostatic diseases · 2021
    Pooled it
  4. Repeatability of QuantitativeJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020
    Trial
  5. Article
  6. [European journal of nuclear medicine and molecular imaging · 2026
    Article
  7. Article
  8. Article
  9. Efficacy and safety of rechallenge with [European journal of nuclear medicine and molecular imaging · 2024
    Article
  10. Correlation of [European journal of nuclear medicine and molecular imaging · 2024
    Article
  11. Review
  12. Review
  13. Metabolic patterns on [European journal of nuclear medicine and molecular imaging · 2023
    Article
  14. Observational
  15. Landmarks in the evolution of prostate biopsy.Nature reviews. Urology · 2023
    Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Anna Katharina SeitzDepartment of Urology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany. seitz_a3@ukw.de.ORCID 0000-0002-1249-5333
Isabel RauscherDepartment of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Bernhard HallerInstitute of Medical Informatics, Statistics and Epidemiology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Markus KrönkeDepartment of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Sophia LutherDepartment of Urology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Matthias M HeckDepartment of Urology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Thomas HornDepartment of Urology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Jürgen E GschwendDepartment of Urology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Markus SchwaigerDepartment of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Matthias EiberDepartment of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Tobias MaurerDepartment of Urology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
TUM Klinikum · DEUniversity of California, Los Angeles · USUniversity of Würzburg · DE

Funding

Deutsche Forschungsgemeinschaft (DFG) SFB 824.
6 · The paper itself

Abstract

purposeTo investigate the value of

methods

resultsBiochemical PR was found in six of seven patients with mCSPC (86%, 95% confidence interval 42% to 99.6%). The concordance rate was higher between BR and RR(PET) than between BR and RR(CT) (6/7 vs. 3/6 patients.

conclusionOur preliminary results suggest that

Indexed as

Positron Emission Tomography Computed TomographyRadiopharmaceuticalsAgedDocetaxelEdetic AcidHumansMaleMiddle AgedNeoplasm Recurrence, LocalProspective StudiesProstatic NeoplasmsRetrospective StudiesDocetaxelEdetic AcidN,N'-bis(2-hydroxy-5-(ethylene-beta-carboxy)benzyl)ethylenediamine N,N'-diacetic acidRadiopharmaceuticals68Ga-PSMA-HBED-CCCastration-resistant prostate cancerCastration-sensitive prostate cancerProstate-specific membrane antigenTherapy response

Identifiers

PMID29185010
OpenAlexW2768562204

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.